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Breast cancer is rare in male patients. Certain predisposing factors, be they genetic  
(e.g., BRCA2 gene mutations) or hormonal (imbalance between estrogen and androgen 
levels), have been implicated in male breast cancer pathophysiology. Male-to-female (MtF) 
transsexualism is a condition that generally involves cross-sex hormone therapy.  
Anti-androgens and estrogens are used to mimic the female hormonal environment 
and induce the cross-sex secondary characteristics. In certain situations, the change in 
the hormonal milieu can be disadvantageous and favor the development of hormone-
dependent pathologies, such as cancer. We report a case of a MtF transgender patient 
who developed breast cancer after 7 years of cross-sex hormonal therapy. The patient was 
found to be BRCA2 positive, and suffered recurrent disease. The patient was unaware of 
being a member of an established BRCA2 mutation-positive kindred. This represents the 
first case of a BRCA2 mutation predisposing to breast cancer in a MtF transgender patient.
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Introduction
Transsexualism occurs with an estimated frequency of 1 
in 11,900–12,900 males and 1 in 30,400–33,800 females 
(van Kesteren et al. 1996, De Cuypere et al. 2007). Male-
to-female (MtF) reassignments occur more frequently 
in middle-aged patients (van Kesteren et  al. 1996). In 
MtF patients, development of female secondary sexual 
characteristics requires hormonal treatment with 
anti-androgens and estrogens. The doses of estrogens 
typically used in MtF patients are higher than those 
administered as substitutive therapy in hypogonadal 
women, and treatment in MtF patients is usually 
continued beyond the typical age of female menopause 
(Gooren et al. 2008).
With the exception of certain skin cancers, breast 
cancer is the most frequently diagnosed neoplasm 
in women, accounting for nearly 29% of all cancers. 
It ranks second in cancer mortality after lung cancer 
(American Cancer Society 2015). Male breast cancer 
represents only 1% in all cases of breast cancer in the 
US (American Cancer Society 2015) and <1% of all male 
cancers (American Cancer Society 2015). At diagnosis, 
male breast cancer patients are, on average, 4 years older 
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than women with breast cancer (64.8 vs 60.9 years) 
(Hill et al. 2005).
Among the genetic modifications that predispose to 
breast cancer, the primary contributors are the BRCA gene 
family. BRCA1 and BRCA2 are tumor suppressor genes 
(Miki et al. 1994, Wooster et al. 1995). Mutations in BRCA1 
and BRCA2 account for 5–10% of cases of female breast 
cancer and 5–20% of male breast cancer (American Cancer 
Society 2015). The transmission of these mutations is 
autosomal dominant. Women in the general population 
have a 7% risk of developing breast cancer by the age 
of 70, whereas the risks of BRCA1 or BRCA2 mutation 
carriers are around 60% and 55%, respectively (Mavaddat 
et al. 2013). The risk of a male BRCA2 mutation carrier 
of developing breast cancer is more than 80 times higher 
than that of the general male population, with a 2.8–7.1% 
chance by the age of 70, rising to 6.9–8.4% by the age of 
80 (Thompson & Easton 2001, Evans et al. 2010).
In this study, we describe what is, to our knowledge, 
the first documented case of breast cancer in a MtF 
transgender patient with a pathogenic BRCA2 mutation. 
We also review the available literature on related issues, 
as well as the pathogenesis of breast cancer in specific 
circumstances.
Case report
A 46-year-old biologically male patient who was 
seeking MtF transition was referred to a specialized 
endocrinologist. He had been diagnosed with sexual 
identity dysphoria and transsexualism 8 years previously. 
Before starting hormone therapy, the patient weighed 
92 kg, had a height of 1.82 m, and had a normal physical 
examination. His medical history was unremarkable 
except for statin-treated hypercholesterolemia and he 
smoked five cigarettes daily. His family history revealed 
type 2 diabetes and prostate cancer in his father. 
The patient had fathered two children, both without 
significant health problems. General hematology and 
biochemistry results (glucose, liver, and renal function 
tests, blood count, lipids) were normal and eventually 
he was started on a hormonal regimen of cyproterone 
acetate 25 mg twice daily, increasing to 50 mg twice daily 
after a month and estradiol gel, two pumps daily.
One year later, follow-up hormonal testing revealed 
suppressed gonadotropins (LH 0.14 IU/mL, FSH 0.11 IU/mL) 
and hyperprolactinemia at 35.97 ng/mL. Estrogen 
and testosterone were at normal female levels. The 
hyperprolactinemia was considered secondary to estrogen 
therapy, as frequently observed in MtF TG patients 
(a pituitary MRI was negative for prolactinoma). Over 
the following years, the MtF transition progressed to 
the patient’s satisfaction with a decrease in male-pattern 
pilosity and an increase in breast size. Biological tests 
and mammography were performed annually and bone 
densitometry was done every 2 years. As the patient was 
satisfied with the results of hormone therapy, no request 
for gender reassignment surgery was made.
After 7 years of hormone therapy, a routine 
mammogram revealed retro-areolar micro-calcifications 
in the right breast, which measured 16 mm in diameter. 
The lesion was judged suspicious and micro-biopsies were 
performed. The histological analysis of the region with 
micro-calcifications revealed a high-grade ductal in situ 
carcinoma (DIN 3) without obvious signs of infiltration. 
The histology of a region without micro-calcifications 
found an intermediate grade ductal carcinoma in situ (DIN 
2) without signs of infiltration. Immunohistochemically, 
80% of cells expressed the estrogen receptor (ER), whereas 
10% expressed the progesterone receptor (PR). HER2 
expression was absent. Hormone therapy was stopped 
immediately after the discovery of the carcinoma. A 
breast MRI was performed to assess the extent of disease. 
It revealed multiple foci of enhancement on the right side 
and a 6 mm focus of enhancement in the left retro-areolar 
region. Second-look ultrasound of the left breast revealed 
an echogenic structure without architectural distortion, 
or cystic/solid lesions. As the 6 mm focus of enhancement 
found on MRI had no corresponding lesion on ultrasound 
and the patient had stopped hormonal therapy, a 
follow-up MRI was recommended with complementary 
biopsy if required. It has remained unchanged to date on 
long-term follow-up.
A right simple mastectomy with sentinel lymph 
node biopsy was performed. The histopathology 
showed focally undifferentiated invasive ductal 
carcinoma (Fig. 1A), without invasion of sentinel nodes 
or the nipple. The margins of resection were clear. 
Analysis of the lesion revealed 100% ER positivity, 
10% PR positivity, a Ki67 index of 50%, and negative 
HER2. Androgen receptor staining showed positivity 
in 80% of cells (Fig.  1B). These results represented a 
formal contraindication to reintroducing hormone 
therapy. Tamoxifen treatment was recommended, but 
was declined by the patient. MRI follow-up of the left 
breast lesion found no progression, therefore the initial 
MRI focus of enhancement was considered to be the 
result of prolonged hormone therapy. Follow-up post-
mastectomy was unremarkable until 30 months after 
surgery, when local recurrence was diagnosed at the site 
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of the mastectomy scar. Radiation therapy and adjuvant 
chemotherapy (epirubicin plus cyclophosphamide, with 
paclitaxel) were instituted.
Genetic analysis of the BRCA1 and BRCA2 genes 
was performed and the presence of the heterozygous 
mutation c.9117G>A in BRCA2 was found. The same 
mutation had already been noted in a family with the 
same surname from the same region; however, the 
patient had made no reference to them previously. 
Further questioning demonstrated that the patient was 
indeed related to the family in which the mutation was 
previously identified (Fig. 1C). Several cases of breast and 
prostate cancers were present in the kindred, expanding 
over four generations.
Discussion
We present the first report of a BRCA2 mutation in a 
MtF transsexual patient with breast cancer. The patient 
was diagnosed with breast cancer at the age of 53, after 
7 years of hormonal treatment. A heterozygous 
c.9117G>A mutation of the BRCA2 gene was found and 
previously unsuspected links to an extensive kindred 
with multiple cases of hormone-related tumors were 
revealed on follow up.
Breast cancer is a rare neoplasm in men. Predisposing 
factors include genetic predisposition, obesity, estrogen–
testosterone imbalance (such as those seen in Kleinfelter 
syndrome) (Brinton et al. 2008). Also potentially implicated 
are radiation exposure, smoking, and alcohol consumption 
(Johansen Taber et al. 2010). BRCA2 gene mutations are 
the main genetic predisposing factor, responsible for 
around 5–20% of male breast cancer cases; fewer cases are 
attributed to BRCA1 mutations (Liede et al. 2004).
MtF TG patients receive hormonal treatment based on 
their transition needs. Anti-androgens are administered 
until removal of the gonads, while estrogens are prescribed 
for longer periods of time, with the dual purpose of 
promoting feminization and avoiding bone density loss. 
Often, the doses administered in this setting are higher 
than those used in the treatment of genetic females for 
hypogonadism, although the aim is to target normal 
values of testosterone and estradiol for genetic females. 
Breast development is a key element in transitioning to a 
female body form and identity. Historically, various breast 
augmentation techniques have been attempted, but the 
current regimens of hormonal treatment often induce the 
desired changes. Prolonged estrogen treatment combined 
with anti-androgens lead to the development of lobules 
and acini and even pseudolactational acinar changes 
(Kanhai et al. 2000).
Breast cancer occurring in males is typically ductal 
carcinoma and is more frequently ER and PR positive than 
in females (Fentiman et al. 2006). Approximately 80% of 
male breast cancer patients have a positive status for both 
Figure 1
Panel A shows a high magnification (200×) H&E stain of invasive breast 
carcinoma resected at mastectomy. In 80% of the carcinoma cells, 
androgen-positive receptor was seen (Panel B; 400× magnification). In 
Panel C, the extended family tree of the BRCA2 mutation positive patient 
is shown with multiple cases of breast and prostate cancers.
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hormone receptors, as occurred in the current patient 
(Chavez-Macgregor et al. 2013). In a large breast cancer 
series in women, BRCA2 mutations were more often 
found to be ER and PR positive than BRCA1 mutations 
(Atchley et al. 2008). Triple negative (ER, PR, HER2) 
cancers were found in 57.1% of BRCA1 positive cases as 
compared with only 23.3% of BRCA2 carriers and 13.8% of 
BRCA-negative patients (Atchley et al. 2008). In the current 
case, the prolonged use of high doses of sex steroids 
(7 years) against the background of a BRCA2 mutation 
may have contributed to cancer formation.
Recent research has focused on the role of the 
androgen receptor in breast cancer. In a series of 135 
breast cancer patients, androgen receptors were found 
in 78% in BRCA2-positive cases compared with 30% of 
BRCA1-positive tumors, whereas BRCA-negative tumors 
expressed AR in 76% of cases (Pristauz et al. 2010). 
Androgens were shown to inhibit the proliferation of 
AR-positive breast cancer cell lines in vitro (Hackenberg 
et al. 1991). BRCA2 seems to be a coactivator of the AR 
(Shin & Verma 2003), which suggests that mutations 
of the BRCA2 could promote breast tumorigenesis by 
reducing the antiproliferative effect of androgens. In our 
patient, AR status was positive in 80% of cells. Hence, the 
anti-androgen therapy and BRCA2 mutation positivity 
could have favored tumorigenesis.
The impact of hormonal treatment on breast cancer 
risks in MtF patients is controversial. Considering 
treatment with estrogen, the total lifetime period 
of exposure is shorter than that for genetic females. 
However, this could be counterbalanced by the higher 
doses, different route of administration, and use of 
more potent compounds. In a large series of transsexual 
patients treated with cross-sex hormones for a period of 
5 to >30 years, breast cancer was not more frequent in 
2307 MtF patients compared with the expected frequency 
for genetically male patients (Gooren et al. 2013). 
Although this is the first report of a BRCA gene mutation 
in a MtF TG person with breast cancer, to date 12 other 
cases of breast cancer in MtF TG patients have been 
reported (Table 1). Most were treated with variable doses 
and formulations of estrogens for >10  years. The most 
frequent type of cancer in this series was invasive ductal 
carcinoma, which corresponds to the type most frequently 
diagnosed in males (Johansen Taber et al. 2010). Among 
the cases that have reported receptor status, only 50% 
were hormone receptor positive, which is less than that 
usually found in male breast cancer (Johansen Taber et al. 
2010). HER2 status was reported in five cases, of which 
four were found to be negative. In the most recent reports, 
genetic alterations in the BRCA genes were sought and no 
anomaly was found. However, older reports mentioned 
familial cases of breast or unknown types of cancer that 
could have had a genetic background.
The c.9117G>A BRCA2 mutation seen in this case has 
already been described in the literature (according to the 
previous nomenclature, c.9345G>A). Codon 9117 is the 
last nucleotide in exon 23 and the G-to-A substitution 
does not alter the amino acid sequence of the protein 
(p.Pro3039Pro). Although it was previously considered 
a variant of unknown significance, Acedo et  al. (2012) 
demonstrated that the c.9117G>A change modifies a 
splice site, resulting in either skipping of exon 23 alone, 
skipping of exons 23 and 24 or deletion of 51 nucleotides 
from exon 23. The mutation was inherited from the 
patient’s paternal branch, and several members of the 
family had prostate and breast cancers. Unfortunately, 
as the family was large, our patient was unaware of the 
BRCA2 mutation detected in second-degree cousins.
A thorough family history is important in the 
evaluation of MtF persons seeking hormonal treatment. 
As in the current case, the awareness of familial risk 
by the patients may not be sufficient. As part of the 
MtF transition process, specific questioning regarding 
familial occurrence of breast and other cancers could be 
beneficial. Apart from breast cancer, BRCA2 carriers also 
have higher risks of developing pancreatic and prostate 
cancers. Pancreatic cancer in male BRCA2 mutation 
carriers is 82.5 times more frequent than in the general 
population (Mersch et al. 2015). The risk of prostate 
cancer is considered to be five times that of the general 
population (Mersch et  al. 2015), but in male patients 
under 65 years, it was found to be 7.3 times increased 
(Breast Cancer Linkage Consortium 1999), whereas in 
men under 56 years, it was 23 times higher (Edwards 
et al. 2003). Moreover, prostate cancer in BRCA2 mutation 
carriers seems to be diagnosed at a younger age and has 
a more aggressive presentation and a worse prognosis 
(Tryggvadottir et al. 2007). Other types of cancer may 
be associated with BRCA2 mutations, such as malignant 
melanoma and various gastrointestinal neoplasias (Breast 
Cancer Linkage Consortium 1999, Liede et  al. 2004, 
Mohamad & Apffelstaedt 2008, Ginsburg et al. 2010), but 
these associations were not confirmed by other studies 
and still remain controversial.
A BRCA2 mutation complicates management 
and follow-up in MtF TG persons. In those who have 
a BRCA2 mutation diagnosed before initiation of 
hormonal therapy, cancer risks and alternatives to 
hormonal therapy (e.g., prosthetic breast augmentation) 
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Table 1 Cases of breast cancer in male-to-female transgender patients reported in the literature
Case Age Type of breast cancer Estrogen treatment and duration IHC Genetics Reference
1 30 Poorly differentiated 
primary mammary 
adenocarcinoma
Estrogen orally and implants 
of estrogen pellets,  
contraceptive pills for over  
6 years and transcutaneous 
mammary estrogen for an 
undetermined period
NR NR Symmers 
(1968) 
2 30 Infiltrating adenocarci-
noma, partly scirrhous 
and partly papillary, 
unequivocal evidence 
of its origin as an 
intraduct carcinoma
Estrogens orally and  
subcutaneous pellets for 
around 5 years, probably 
estrogen-containing cream 
applied on breasts for over  
2 years
NR NR Symmers 
(1968)
3 45 High-grade infiltrating 
ductal carcinoma
1.25 mg/day oral conjugated 
estrogen for 11 years
ER− (but false 
negative pos-
sible), PR+





4 50 Invasive ductal  
carcinoma
0.625 mg/day oral conjugated 
estrogen for 14 years
ER−, PR not 
reported
NR Ganly & 
Taylor 
(1995)
5 46 Secretory carcinoma Long-term cross-hormone 
treatment
ER−, PR−, HER2− NR, grandmother died of 
cancer (unknown)
Grabellus 
et al.  
(2005)
6 58 Adenocarcinoma Estrogen treatment for  
>11 years
ER+, PR+ NR; mother with cancer Dhand & 
Dhaliwal 
(2010)
7 43 Invasive ductal  
carcinoma
Oral conjugated estrogen and 
cyproterone acetate for  
7 years, then intermittent 
use for 3 years, then 
estradiol valerate 4 mg/day 
and cyproterone acetate  
50 mg/day for 5 years
ER−, PR−, HER2− Negative family history for 




8 57 Ductal carcinoma Various estrogen preparations 
for 36 years
ER+, PR−, HER2− NR Gooren 
et al. 
(2013)
9 46 Initial histology of 
breast tumor benign; 
10 years later  
generalized poorly 
differentiated 
carcinoma with a 
probable, but uncon-
firmed breast origin
Estrogens for 17 years Not reported NR Gooren 
et al. 
(2013)
10 55 Poorly differentiated 
invasive ductal 
carcinoma
Oral conjugated estrogens for 
unknown period and 
estradiol valerate 20 μg/
month for 30 years
ER−, PR−, HER2+ NR Maglione 
et al. 
(2014)
11 65 Ductal carcinoma in situ Oral conjugated estrogens  
2.5 mg/day for 13 years
ER+, PR+ Family history of breast 
cancer in father, maternal 
aunt and ovarian cancer 




12 60 Infiltrating ductal 
carcinoma
Unspecified hormone therapy 
for 8 years
ER+, PR+, HER2− BRCA1 and 2 negative, no 




13 53 Focally undifferentiated 
ductal carcinoma
Estradiol gel 2 pumps/day  
and cyproterone acetate  
100 mg/day for 7 years
ER+, PR+, HER2− Breast cancer in four 
female and one male 2nd 
degree and other cousins; 
prostate cancer in father, 
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should be discussed. Male BRCA2 mutation carriers 
should undergo surveillance that includes regular self 
and clinical breast examination, but in men, imaging 
studies and prophylactic mastectomy are not part of 
guideline recommendations (National Comprehensive 
Cancer Network 2016). In BRCA2-positive MtF cases that 
have hormone-induced breast formation, it would seem 
prudent to adopt yearly screening mammography and/
or MRI, as would be the case in adult genetic females 
(Balmaña et al. 2011, National Comprehensive Cancer 
Network 2016). BRCA2-positive patients have higher risks 
for prostate cancer. As complications of prostatectomy 
can be significant, removal of the prostate is generally 
not part of the sex reassignment surgery of MtF patients 
(Hembree et al. 2009). Prostate examinations should 
be performed at least once a year along with prostate-
specific antigen measurement. During follow-up, the risk 
of other potential BRCA2-associated cancers should be 
kept in mind.
Nearly 1/11,000 males have gender identity 
dysphoria that leads to MtF transsexualism. The past few 
decades have seen a better acceptance of transsexualism 
and increased understanding of the particular healthcare 
needs of MtF persons. In parallel, there has been a greater 
public awareness of the role of genetic mutations of BRCA 
genes in the risk of endocrine-related cancers. As MtF TG 
persons attain their desired gender through hormonal 
treatment, they develop a new physical and personal 
identity. In parallel they also undergo an important 
transition in their cancer risks due to hormonal therapy. 
This case highlights the convergence of two topical 
endocrine-related issues: MtF TG and BRCA2 mutation-
related cancer risk. It raises an infrequent but crucial 
aspect in the comprehensive endocrine care of MtF TG 
individuals.
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